Latest Interviews
Showing 1–4 of 4 interview transcripts.
Clear all filters- a16z46 min
Hey Tech, Come to Healthcare
In a 2022 analysis, analysts BJ and Daisy predict that consumer health technology will produce the world's first trillion-dollar company by leveraging a $4 trillion U.S. market where 88% of the population faces metabolic challenges. The event details how artificial intelligence and post-pandemic cultural shifts are enabling a transition from reactive sick care to predictive, home-centric prevention while bypassing traditional incumbent barriers through new "payvider," marketplace, and financial infrastructure models. These strategies aim to unify fragmented health data and engineer behavioral change, ultimately positioning tech founders with hybrid clinical expertise to replace legacy systems with AI-driven, high-UX solutions.
- a16z1h 12m
2023 Big Ideas in Technology (Part 2)
Anish Acharya, Angela Strange, Michelle Volz, Ryan McEntush, Vijay Pande, Julie Yoo
Anish Charya and Angela Strange outline transformative fintech strategies where GPT-driven credit counseling scales labor efficiency while software-enabled compliance converts regulatory burdens into strategic competitive moats. Parallel discussions led by Michelle Foles and Ryan McIntosh highlight how Small Modular Reactors and space supply chain overhauls will redefine energy production and industrial supremacy through advanced manufacturing and resource extraction. These innovation themes converge with healthcare predictions from Vijay Pandey and Julie Yu, who forecast the rise of consumer health tech and value-based care stacks to replace legacy fee-for-service models with outcome-focused infrastructure.
- a16z48 min
a16z Podcast | Incenting Innovation Inside, Loonshots to Moonshots
Safi Bahcall, Vijay Pande, Sonal Chokshi
This presentation defines "loonshots" as high-risk creative processes distinct from their destination goals, arguing that established organizations often suppress them due to misaligned incentives that favor political survival over innovation. By applying four structural control parameters—equity fraction, return on politics, skill fit, and management span—leaders can engineer a dynamic equilibrium that allows creative "artists" and execution-focused "soldiers" to coexist and successfully transfer ideas to the market. Historical case studies of figures like Vannevar Bush, Steve Jobs, and institutions such as Xerox PARC illustrate how shifting from "Moses" leadership to "gardener" models is essential for sustaining the organizational phase transitions required to turn early failures into transformative moonshots.
- a16z59 min
a16z Podcast | The Science and Business of Innovative Medicines
Jorge Conde, Vijay Pande, Sonal Chokshi, Vas Narasimhan
Novartis transformed its portfolio through a $50 billion restructuring that divested consumer healthcare to prioritize advanced therapies, data science, and proprietary platforms for cell and gene treatments. Under CEO Vas Narasimhan, the company enforces strict "standard of care" mandates for project approval, integrates market access early in development, and invested $15 billion to own specialized infrastructure while leveraging AI for financial forecasting and pathology analysis. This strategic pivot targets a 10% clinical success rate by shifting from bespoke drug development to modular platforms and dedicated digital innovation centers, positioning the firm to address undruggable targets and future modalities like xenotransplantation.